Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

  • Codony-Servat, Jordi
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Asensio, Elena
  • Montironi, Carla|||0000-0002-1453-2193
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Marín Aguilera, Mercedes
  • Horndler, Carlos
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
  • Rubini, Michele
  • Jares, Pedro
  • Reig, Oscar|||0000-0003-1166-6943
  • Victoria, Iván
  • Gaba, Lydia
  • Martín-Richard, Marta|||0000-0003-4933-2463
  • Alonso Orduña, Vicente|||0000-0003-2280-1004
  • Escudero, Pilar
  • Fernández-Martos, Carlos
  • Feliu, Jaime|||0000-0003-4867-1420
  • Méndez, Jose Carlos
  • Méndez, Miguel
  • Gallego Plazas, Javier|||0000-0002-0584-1242
  • Salud, Antonieta
  • Rojo, Federico|||0000-0001-9989-0290
  • Castells, Antoni|||0000-0001-8431-2033
  • Prat, Aleix|||0000-0003-2377-540X
  • Rosell, Rafael|||0000-0003-0817-3400
  • García-Albéniz, Xabier
  • Camps Polo, Jordi|||0000-0003-2929-4228
  • Maurel, Joan|||0000-0002-9413-5592
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. We analysed time to progression, overall survival, and the mutational status of RAS, BRAF and nuclear p-IGF-1R expression by immunohistochemistry, in 470 metastatic CRC patients. The effect of IGF-1R activation and distribution was also assessed using cellular models of CRC and RNAi for functional validation. Nuclear IGF-1R increased in metastatic tumours compared to paired untreated primary tumours, and significantly correlated with poor overall survival in mCRC patients. In vitro, chemo-resistant cell lines presented significantly higher levels of IGF-1R expression within the nuclear compartment, and PIAS3, a protein implicated also in the sumoylation process of intranuclear proteins, contributed to IGF-1R nuclear sequestration, highlighting the essential role of PIAS3 in this process. Intriguingly, we observed that ganitumab, an IGF-1R blocking-antibody used in several clinical trials, and dasatinib, an SRC inhibitor, increased the nuclear localisation of IGF-1R. Our study demonstrates that IGF-1R nuclear location might lead to chemotherapy and targeted agent resistance.